1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is 36,50€ (+1.515,04%). The median is 36,50€ (+1.515,04%).
| Buy |
4 |
| Hold |
1 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 0.00 | - |
| Gross profit | 0.00 | - |
| Net profit | −7.44m | 4,11% |
| EBITDA | −7.44m | 4,11% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 22.96m€ |
Number of shares | 9.98m |
52-week high/low | 16,62€ - 1,46€ |
| Dividends | No |
Beta | 1,25 |
P/E ratio | −0,62 |
PEG ratio | 0,02 |
P/B ratio | 0,89 |
P/S ratio | 0,00 |
Company profile
| Name | Atossa Therapeutics |
| CEO | Steven C. Quay |
| Employees | 16 |
Discover assets
Shareholders of Atossa Therapeutics also invest in the following assets
